Abstract 214P
Background
Translocation renal cell carcinoma (TRCC) represents 1% to 5% of all cases of renal cell carcinoma (RCC), with the highest frequency among children and young adults. Management of these tumors is ill defined. This is a retrospective analysis of treatment outcome in adult patient 18 years or above treated at our hospital between Janaury 2013 to November 2019.
Methods
Clinical and pathological data of 26 patients from a single institution diagnosed with TRCC between January 2013 and November 2019 were retrospectively reviewed. We analyzed our data of patients treated with Surgery only or who progressed after surgery and treated with systemic therapy or who upfront due to unresectable or metastatic disease treated with systemic therapy with respect to Event free survival and overall survival.
Results
Between Jan 2013 to Nov 2018, 26 adult patients were treated at our centre. Out of 26 patients 25 had radical surgery after evaluation and 1 had metastatic disease who was started on systemic therapy. Out 25 patient who were treated with radical surgery, 16 patients progressed and they were started on systemic therapy. Median EFS and median OS among overall population was 22 month and 30 month respectively. Among 16 patient who were treated with systemic therapy, median EFS to first line therapy was 8 month and to second line therapy was 2.5 month. Median OS was 17 month.
Conclusions
TFE RCC is rarely seen but carries significant risk of disease progression with potential response to targeted therapy of short duration.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Ajaykumar Singh.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
276P - Sarcopenia to predict overall survival in head and neck cancer patients receiving chemotherapy: A systematic review and meta-analysis
Presenter: Felix Kwenandar
Session: e-Poster Display Session
277P - Tegafur/uracil, platinum and cetuximab (UPEx) as first line treatment in frail patients with recurrent or metastatic head and neck squamous cell carcinoma
Presenter: Meng-che Hsieh
Session: e-Poster Display Session
278P - Serial assessment of parotid volume changes during radical chemoradiation of locally advanced head and neck cancer: Its implications in practice of adaptive radiotherapy
Presenter: Aathira T S
Session: e-Poster Display Session
279P - Clinico pathological characteristics and survival outcome in oral cavity cancer with masticator space involvement (T4b): A retrospective single institutional experience
Presenter: Abdulla Kunnummal Palathinkara
Session: e-Poster Display Session
280P - Safety and efficacy of concurrent chemoradiotherapy for head and neck cancers in younger versus older patients: Post hoc analysis of a randomized control trial
Presenter: Vanita Noronha
Session: e-Poster Display Session
281P - Prevalence of premalignant lesions and oral cancer among tobacco-using tea plantation workers of Nilgiri Hills, Tamilnadu, India
Presenter: Delfin Lovelina Francis
Session: e-Poster Display Session
282P - Filipino head and neck cancer patients and their quality of life
Presenter: Frederic Ivan Ting
Session: e-Poster Display Session
283P - Descriptive epidemiology of head and neck cancer in Niger: First results from the National Cancer Registry
Presenter: Salamatou Mamoudou Garba
Session: e-Poster Display Session
284P - Outcomes of metronomic adjuvant chemotherapy with tegafur-uracil in locally advanced head and neck squamous cell carcinoma
Presenter: Tsung-jang Yeh
Session: e-Poster Display Session
285P - Comparison of induction chemotherapy plus concurrent chemoradiotherapy and concurrent chemoradiotherapy alone in locally advanced nasopharyngeal carcinoma: A meta-analysis
Presenter: Xu Guoqiang
Session: e-Poster Display Session